Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment advances for CMV retinitis.

F M Rahhal1

  • 1Department of Ophthalmology, New York Presbyterian Hospital-Cornell Medical Center, New York, NY, USA.

The AIDS Reader
|May 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of the ganciclovir implant in the setting of silicone oil vitreous substitute.

Retina (Philadelphia, Pa.)·2000
Same author

Fluorophotometry in patients with human immunodeficiency virus with and without cytomegalovirus retinitis.

Ophthalmology·1999
Same author

Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·1998
Same author

Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance.

Archives of ophthalmology (Chicago, Ill. : 1960)·1998
Same author

The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure.

American journal of ophthalmology·1998
Same author

Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS).

Ophthalmology·1997

Newer therapies for cytomegalovirus (CMV) retinitis offer improved administration and reduced toxicity. Highly active antiretroviral therapy (HAART) is decreasing CMV retinitis incidence, prompting research into novel management strategies.

Area of Science:

  • Ophthalmology
  • Virology
  • Pharmacology

Background:

  • Cytomegalovirus (CMV) retinitis historically required intensive systemic therapy.
  • Treatment options were limited to daily central venous catheter infusions.
  • This posed significant challenges for patient management and adherence.

Purpose of the Study:

  • To review the evolution of CMV retinitis management.
  • To highlight advancements in therapeutic approaches.
  • To discuss the impact of HAART on CMV retinitis incidence and future strategies.

Main Methods:

  • Review of historical and current treatment modalities for CMV retinitis.
  • Discussion of systemic versus local therapeutic options.
  • Analysis of the influence of highly active antiretroviral therapy (HAART) on disease epidemiology.

Related Experiment Videos

Main Results:

  • Introduction of cidofovir allows for less frequent peripheral IV administration.
  • Local therapies (intraocular device, intravitreal injections) reduce toxicity and enhance ocular drug absorption.
  • HAART has led to a significant decline in CMV retinitis incidence.

Conclusions:

  • CMV retinitis management has shifted towards less toxic and more convenient options.
  • The decreasing incidence due to HAART necessitates re-evaluation of natural history and future treatment paradigms.
  • Further research into CMV retinitis in the HAART era is crucial for optimizing patient care.